Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 89

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 89
---
 Securities Administrators National Instrument 51-102 “ Continuous Disclosure Obligations”, or the Instrument, we are
required to disclose in the context of sending an information circular to shareholders all compensation paid, payable, awarded, granted,
given or otherwise provided, directly or indirectly, by the issuer, or a subsidiary of the issuer, to each Named Executive Officer (as
such term is defined in the Instrument) and director, in any capacity, including, for greater certainty, all plan and non-plan compensation,
direct and indirect pay, remuneration, economic or financial award, reward, benefit, gift or perquisite paid, payable, awarded, granted,
given, or otherwise provided to the NEO or director for services provided, directly or indirectly, to the issuer or a subsidiary of the
issuer. Such disclosure will not be as extensive as that required of a U. S. domestic issuer. Our officers, directors and principal shareholders
will also be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition,
we will not be required under the Exchange Act to file reports and financial statements with the SEC as frequently or as promptly as U. S.
domestic companies whose securities are registered under the Exchange Act and we will be exempt from filing quarterly reports with the
SEC under the Exchange Act. Moreover, we will not be required to comply with Regulation FD, which restricts the selective disclosure of
material information, although we intend to voluntarily adopt a corporate disclosure policy substantially similar to Regulation FD. These
exemptions and leniencies will reduce the frequency and scope of information and protections to which you may otherwise have been eligible
in relation to a U. S. domestic issuer.

We would lose our foreign private issuer status
if a majority of our shares are owned by U. S. residents and a majority of our directors or executive officers are U. S. citizens or residents
or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. The regulatory and compliance costs
to us under U. S. securities laws as a U. S. domestic issuer may be significantly higher. If we are not a foreign private issuer, we will
be required to file periodic reports and registration statements on U. S. domestic issuer forms with the SEC, which are more detailed and
extensive than the forms available to a foreign private issuer. We may also be required to modify certain of our policies to comply with
accepted governance practices associated with U. S.